Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1997 1
1998 1
1999 2
2000 1
2001 1
2002 2
2003 4
2004 3
2005 2
2006 2
2007 5
2008 4
2009 4
2010 6
2011 2
2012 5
2013 7
2014 7
2015 10
2016 6
2017 7
2018 8
2019 8
2020 8
2021 17
2022 13
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following terms were ignored: %, %, %, %
The following terms were not found in PubMed: 22Scheeringa, 5BAuthor
Page 1
Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
Narita I, Tsubakihara Y, Uchiyama T, Okamura S, Oya N, Takahashi N, Gejyo F; MR13A9-4 Trial Investigators. Narita I, et al. JAMA Netw Open. 2022 May 2;5(5):e2210339. doi: 10.1001/jamanetworkopen.2022.10339. JAMA Netw Open. 2022. PMID: 35511180 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled, 4-arm phase 2 trial was conducted from February 1, 2019, to October 22, 2019, at 94 sites in Japan. Patients with moderate to severe pruritus receiving hemodialysis were enrolled. ...The …
DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled, 4-arm phase 2 trial was conducted from February 1, 201 …
Erratum.
[No authors listed] [No authors listed] Mult Scler. 2016 Oct;22(12):NP9-NP11. doi: 10.1177/1352458515585718. Epub 2015 Jun 3. Mult Scler. 2016. PMID: 26041800
Adherence to home-based balance training was highest in the exergame group.Goble et al.(24)WiiCase study. N=1, 28 year old Male. Relapsing-remitting MS since age 11. EDSS 5.0. INTERVENTION: Six-week balance training, 3x30 mins per week. ...Over first two weeks 12% decrease …
Adherence to home-based balance training was highest in the exergame group.Goble et al.(24)WiiCase study. N=1, 28 year old Male. Relapsing-r …
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
Ryerson LZ, Foley JF, Defer G, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Sinks S, Kuhelj R, Bodhinathan K, Lasky T. Ryerson LZ, et al. Mult Scler Relat Disord. 2023 Apr;72:104561. doi: 10.1016/j.msard.2023.104561. Epub 2023 Feb 11. Mult Scler Relat Disord. 2023. PMID: 36931078 Free article. Clinical Trial.
At week 72, there were no significant differences between Q6W and Q4W groups in LSM change from baseline for T25FW (0.00, P = 0.975), 9HPT (dominant [0.22, P = 0.533] or nondominant [0.09, P = 0.862] hand), or SDMT (-1.03, P = 0.194). Similarly, there were no significant d …
At week 72, there were no significant differences between Q6W and Q4W groups in LSM change from baseline for T25FW (0.00, P = 0.975), 9HPT ( …
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant.
Jamieson C, Popova V, Daly E, Cooper K, Drevets WC, Rozjabek HM, Singh J. Jamieson C, et al. Health Qual Life Outcomes. 2023 May 8;21(1):40. doi: 10.1186/s12955-023-02113-1. Health Qual Life Outcomes. 2023. PMID: 37158911 Free PMC article. Clinical Trial.
The outcome assessments included the European Quality of Life Group, Five Dimension, Five Level (EQ-5D-5L), EQ-Visual Analogue Scale (EQ-VAS), and Sheehan Disability Scale (SDS). The health status index (HSI) was calculated using EQ-5D-5L scores. RESULTS: The full a …
The outcome assessments included the European Quality of Life Group, Five Dimension, Five Level (EQ-5D-5L), EQ-Visual Analogue Scale …
The Burden of Migraine on Quality of Life in Chronic Rhinosinusitis.
Derbarsegian A, Adams SM, Phillips KM, Sedaghat AR. Derbarsegian A, et al. Laryngoscope. 2023 Dec;133(12):3279-3284. doi: 10.1002/lary.30662. Epub 2023 Mar 27. Laryngoscope. 2023. PMID: 36971228
METHODS: A total of 213 adult patients with CRS were recruited. All participants completed the 22-item Sinonasal Outcome Test (SNOT-22), from which total and validated nasal, ear/facial pain, sleep, and emotional subdomain scores were calculated, and the 5-dimension …
METHODS: A total of 213 adult patients with CRS were recruited. All participants completed the 22-item Sinonasal Outcome Test (SNOT- …
The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications.
Young CA, Mills R, Langdon D, Sharrack B, Majeed T, Kalra S, Footitt D, Rog D, Harrower T, Nicholas R, Woolmore J, Thorpe J, Hanemann CO, Ford H, Paling D, Ellis C, Palace J, Constantinescu C, Tennant A. Young CA, et al. J Neurol Sci. 2022 May 15;436:120188. doi: 10.1016/j.jns.2022.120188. Epub 2022 Feb 18. J Neurol Sci. 2022. PMID: 35303502
METHODS: Participants completed serial questionnaire packs, including Unidimensional Self-efficacy-MS (USE-MS) scale, for the Trajectories of Outcome in Neurological Conditions-MS (TONiC-MS) study over an average 46-month period. ...RESULTS: 5887 pwMS …
METHODS: Participants completed serial questionnaire packs, including Unidimensional Self-efficacy-MS (USE-MS) scale, for the …
Humanistic Burden of Huntington Disease: Evidence From the Huntington Disease Burden of Illness Study.
Rodriguez Santana I, Frank S, Doherty M, Willock R, Hamilton J, Hubberstey H, Stanley C, Vetter L, Winkelmann M, Dolmetsch RE, Li N, Ratsch S, Ali TM. Rodriguez Santana I, et al. Neurol Clin Pract. 2022 Dec;12(6):e172-e180. doi: 10.1212/CPJ.0000000000200095. Neurol Clin Pract. 2022. PMID: 36540140 Free PMC article.
Patient-reported outcomes included the 5-level EQ-5D version (EQ-5D-5L), Short-Form-(SF)-36 v2 (and SF-6-Dimension [SF-6D] utility), Huntington Quality of Life Instrument (H-QoL-I), and the Work Productivity and Activity Impairment Specific Health Problem. ...Partic …
Patient-reported outcomes included the 5-level EQ-5D version (EQ-5D-5L), Short-Form-(SF)-36 v2 (and SF-6-Dimension [SF-6D] uti …
Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
Hümmert MW, Bütow F, Tkachenko D, Ayzenberg I, Pakeerathan T, Hellwig K, Klotz L, Häußler V, Stellmann JP, Warnke C, Goereci Y, Etgen T, Luessi F, Bronzlik P, Gingele S, Lauenstein AS, Kleiter I, Rommer PS, Paul F, Bellmann-Strobl J, Duchow A, Then Bergh F, Pul R, Walter A, Pellkofer H, Kümpfel T, Pompsch M, Kraemer M, Albrecht P, Aktas O, Ringelstein M, Senel M, Giglhuber K, Berthele A, Jarius S, Wildemann B, Trebst C; Neuromyelitis Optica Study Group (NEMOS). Hümmert MW, et al. Neurol Neuroimmunol Neuroinflamm. 2023 Jan 24;10(2):e200082. doi: 10.1212/NXI.0000000000200082. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36693760 Free PMC article.
Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clinical characteristics were retrieved from the NEMOS database. ...The reported HRQoL did not decline compared with a prepandemic assessment (m …
Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clin …
Thermally Stable Terbium(II) and Dysprosium(II) Bis-amidinate Complexes.
Jin PB, Luo QC, Gransbury GK, Vitorica-Yrezabal IJ, Hajdu T, Strashnov I, McInnes EJL, Winpenny REP, Chilton NF, Mills DP, Zheng YZ. Jin PB, et al. J Am Chem Soc. 2023 Dec 27;145(51):27993-28009. doi: 10.1021/jacs.3c07978. Epub 2023 Nov 24. J Am Chem Soc. 2023. PMID: 37997752 Free PMC article.
The thermostable four-coordinate divalent lanthanide (Ln) bis-amidinate complexes [Ln(Piso)(2)] (Ln = Tb, Dy; Piso = {(NDipp)(2)C(t)Bu}, Dipp = C(6)H(3)(i)Pr(2)-2,6) were prepared by the reduction of parent five-coordinate Ln(III) precursors [Ln(Piso)(2)I] (Ln = Tb, Dy) with KC(8 …
The thermostable four-coordinate divalent lanthanide (Ln) bis-amidinate complexes [Ln(Piso)(2)] (Ln = Tb, Dy; Piso = {(NDipp)(2)C(t)Bu}, Dip …
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, Korotaeva TV, Lavie F, Noël W, Nurmohamed MT, Sfikakis PP, Sharaf M, Theander E, Smolen JS. Gossec L, et al. Arthritis Res Ther. 2023 Jun 23;25(1):109. doi: 10.1186/s13075-023-03058-y. Arthritis Res Ther. 2023. PMID: 37353788 Free PMC article.
METHODS: In PsABio (NCT02627768), a prospective, observational study, patients with PsA that were prescribed first- to third-line ustekinumab or a TNFi, and remained on that drug for 3 years, were analysed for change in baseline in PROs (EuroQol-5 dimensions health state VAS [EQ- …
METHODS: In PsABio (NCT02627768), a prospective, observational study, patients with PsA that were prescribed first- to third-line ustekinuma …
134 results